Oragenics Inc. (OGEN)

0.9293 +0.0437 (+4.935%)

IEX Real-Time Price

November 16, 2018 EST.

NYSE American : Healthcare

Prev Close 0.8856

Price Open 0.9975

Volume: 2.18M

Avg Volume: 4.23M

Market Cap: 27.35M

P/E Ratio -1.27

52 Wk Range 0.38-4.712



OGEN Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-31
19.26M
1.31M
0.09
6.83%

2018-10-15
19.26M
1.94M
0.10
10.07%

2017-12-29
39.37M
286,908
0.90
0.73%

2017-12-15
39.37M
112,379
0.54
0.29%




OGEN Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-09-03
Q2 2018
N/A
-0.41 (2)
0.00
0.00

2018-08-13
Q2 2018
N/A
-0.41 (2)
-0.38
0.03

2018-07-02
Q1 2018
N/A
0.00 (0)
0.00
0.00

2017-11-13
Q3 2017
N/A
0.00 (0)
0.00
0.00

News

Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis (2018-11-15 16:15 Business Wire)

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute a…

 

Oragenics reports Q3 results (2018-11-15 00:21 SeekingAlpha)

Oragenics (NYSEMKT: OGEN ): Q3 GAAP EPS of -$0.35. Cash and equivalents of $13.81M Press Release More news on: Oragenics, Inc., Earnings news and commentary, Healthcare stocks news, ,

 

Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update (2018-11-14 19:27 Business Wire)

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results for the quarter ended September 30, 2018. As of September 30, 2018, the Company reported $13.8 millio…

 


Statistics

Shares Outstanding: 29.43M

Top 15 Institution Percent: 8.60

Price To Sales: N/A

Price To Book: 1180.81

Revenue: N/A

Gross Profit: N/A

Cash: 6.17M

Debt: N/A

Return On Assets: -97.06

Return On Equity: -289.39

Profit Margin: N/A

Price History

Beta: 0.91

50-day Moving Avg: 1.02

200-day Moving Avg: 1.27

YTD Change: -58.88

5-day Change: -2.53

1-month Change: -29.60

3-month Change: 78.71

6-month Change: -35.47

1-year Change: -72.68

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Oragenics Inc.

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.oragenics.com

Oragenics Inc is a biopharmaceutical company which engages in the discovery, development and commercialization of technologies associated with oral health, broad spectrum antibiotics and other general health benefits.